FDA Issues Sales Ban on Vuse Solo Menthol E-Cigarette Products

Mar.18.2023
FDA Issues Sales Ban on Vuse Solo Menthol E-Cigarette Products
The FDA bans two Vuse Solo menthol e-cigarette products due to lack of evidence supporting their public health benefit.

On March 17th, the US Food and Drug Administration (FDA) issued a ban on the sale of two menthol-flavored e-cigarette products from the Vuse Solo brand owned by Reynolds American Inc. The ban is applicable to "Vuse Replacement Cartridge Menthol 4.8% G1" and "Vuse Replacement Cartridge Menthol 4.8% G2".


Currently, Renault is not allowed to sell these products in the United States or they will face enforcement action from the FDA. However, the company can resubmit an application to address the product defects involved in the MDO constraints.


The FDA has requested that applicants disclose whether mint-flavored e-cigarettes are more beneficial compared to tobacco-flavored e-cigarettes.


The FDA evaluates tobacco products for public health standards before they can be marketed through a Pre-Market Tobacco Application (PMTA). Upon reviewing the company's PMTA, the FDA determined that the application lacked sufficient evidence to prove that allowing the product to be sold would be in the best interest of public health, as required by the 2009 Family Smoking Prevention and Tobacco Control Act. Specifically, the evidence presented by the applicant did not demonstrate that mint-flavored e-cigarettes were less harmful to the adult smoking population compared to tobacco-flavored e-cigarettes.


Existing evidence, including data from the 2022 National Youth Tobacco Survey (NYTS), suggests that non-tobacco flavored e-cigarettes, including mint-flavored e-cigarettes, pose significant risks in terms of attraction, intake, and use among youths. In contrast, data indicates that tobacco-flavored e-cigarettes do not have the same appeal to young people and therefore do not pose the same risks. Given these existing differences in youth risks, the applicant needs to provide strong evidence to demonstrate that the use of their mint-flavored e-cigarette products can greatly reduce cigarette use among adult smokers compared to tobacco-flavored e-cigarettes.


According to data from The New York Times, Vuse is the second most popular brand among teenage e-cigarette users. The FDA aims to ensure not only that the manufacturers comply, but also that the distributors and retailers comply. Retailers who have any doubts about their inventory should contact Reynolds.


This is not the first action taken by the FDA.


This recent action is just one of many taken by the FDA to ensure that tobacco products sold in the United States undergo scientific review and receive PMTA approval. So far, the agency has received over 26 million PMTA applications and has made decisions on 99% of them. Currently, the FDA has approved 23 flavored electronic cigarettes for sale or distribution in the United States, which are the only ones allowed on the market legally.


The FDA has also rejected millions of non-compliant marketing applications, including 10 non-tobacco-flavored e-cigarette pods under the Vuse Solo brand. On January 24 of this year, the FDA also issued marketing bans (MODs) for two products by Reynolds American Inc., including the Vuse Vibe Tank Menthol 3.0% and Vuse Ciro Cartridge Menthol 1.5%.


In October 2022, the FDA issued an MDO (Modified Risk Order) for several mint-flavored e-cigarette products sold by Logic Technology Development. This was the first time the FDA had issued an MDO for products containing menthol after undergoing scientific review. However, a few days later, Logic received an order from the US Third Circuit Court of Appeals, which temporarily suspended the MDO's enforcement.


References:


The FDA has refused to allow two Vuse Solo menthol e-cigarette products to be marketed.


Related reading:


The FDA has announced that it has rendered decisions on 99% of the PMTA applications for electronic cigarettes, and intends to review the remaining popular products by the end of the year.


The FDA issues a marketing refusal order for two Vuse products.


Renault, a tobacco company owned by British American Tobacco, plans to appeal against the marketing ban imposed by the FDA.


The FDA has filed civil lawsuits and imposed fines against four electronic cigarette liquid manufacturers for the first time.


The FDA has scheduled a public hearing on April 12th to discuss the creation of new regulations for the manufacturing of tobacco products.


This document has been generated through artificial intelligence translation and is provided solely for the purposes of industry discourse and learning. Please note that the intellectual property rights of the content belong to the original media source or author. Owing to certain limitations in the translation process, there may be discrepancies between the translated text and the original content. We recommend referring to the original source for complete accuracy. In case of any inaccuracies, we invite you to reach out to us with corrections. If you believe any content has infringed upon your rights, please contact us immediately for its removal.

Malaysia Urged to Act as Teen E-cigarette Use Rises
Malaysia Urged to Act as Teen E-cigarette Use Rises
As youth vaping continues to rise in Malaysia, the Malaysian Thoracic Society and the Lung Foundation are urging the government to immediately enforce the Control of Smoking Products for Public Health Act 2024. Experts warn that many e-cigarettes are designed to resemble toys, candies or USB drives, making them highly appealing to teenagers and potentially acting as a gateway to drug use.
May.20 by 2FIRSTS.ai
Ispire Reports FY2025 Q3 Revenue Down 12.7% to $26.2M; Secures Temporary Nicotine Production License in Malaysia
Ispire Reports FY2025 Q3 Revenue Down 12.7% to $26.2M; Secures Temporary Nicotine Production License in Malaysia
Ispire’s FY2025 Q3 revenue fell 12.7% to $26.2 million, with net loss widening to $10.9 million. The company is shifting manufacturing to Malaysia, aiming to cut costs by $8 million annually, and has obtained a temporary nicotine production license. It also filed a blockchain-based PMTA component with the FDA and launched the Sprout™ cannabis device with Raw Garden to grow its presence in emerging markets.
May.13 by 2FIRSTS.ai
2Firsts Interviews Harm Reduction Policy Expert Jeannie Cameron: WHO’s Rejection of Harm Reduction Is Undermining Global Tobacco Control
2Firsts Interviews Harm Reduction Policy Expert Jeannie Cameron: WHO’s Rejection of Harm Reduction Is Undermining Global Tobacco Control
As part of its GFN media partnership, 2Firsts spoke with FCTC expert Jeannie Cameron, who warns that the WHO’s rejection of harm reduction is leading global tobacco control efforts off course.
Jun.18
Itsuwa Posts 194% Drop in 2024 Net Profit with $2.7M Loss, to Focus on Modular and Eco-Friendly E-Cigarettes
Itsuwa Posts 194% Drop in 2024 Net Profit with $2.7M Loss, to Focus on Modular and Eco-Friendly E-Cigarettes
Itsuwa Technology (NEEQ: 833767) released its 2024 annual report, reporting revenue of 283 million yuan, down 12.59% year-on-year, and a net loss of 19.66 million yuan, a 194.47% decline from the previous year. The company attributed the loss to intense competition and product homogeneity in overseas markets, as well as rising labor costs. Its gross profit margin dropped to 30%, while R&D spending accounted for 9.12% of revenue. Going forward, the company plans to focus on developing eco-friendl
May.13 by 2FIRSTS.ai
Hong Kong, China Cracks Down on E-Cigarette Smuggling with HK$20 Million Seizure
Hong Kong, China Cracks Down on E-Cigarette Smuggling with HK$20 Million Seizure
Hong Kong's Independent Commission Against Corruption (ICAC) has arrested 16 individuals for allegedly bribing logistics workers to distribute illegal e-cigarettes. The operation led to the seizure of over 200,000 e-cigarette products valued at HK$20 million, marking the largest such case since the city's vaping ban.
May.09 by 2FIRSTS.ai
BAT: Accelerating Smokeless Transition, with MENA as a Global Strategic Focus
BAT: Accelerating Smokeless Transition, with MENA as a Global Strategic Focus
British American Tobacco accelerates transformation towards smoke-free future in MENA region, playing crucial role in harm reduction.
Jun.11 by 2FIRSTS.ai